Seismic Therapeutic Valuation, Funding & Investors

Culture Biosciences is a San Francisco-headquartered biotech firm offering a cloud-connected biomanufacturing platform with robotic bioreactors. Its system enables parallel experimentation for process development in fermentation and cell culture, serving pharmaceutical and industrial biotech clients. Founded in 2016, the company has raised over $100 million in funding and operates a 20,000-square-foot facility in South San Francisco for high-throughput runs.

Activ Surgical is a Boston-headquartered digital surgery company developing intelligent surgical platforms powered by computer vision, AI, analytics, and machine learning. Its flagship ActivSight imaging system provides real-time visual feedback during procedures, enhancing tissue identification and perfusion assessment to reduce complications. The scalable software integrates with existing laparoscopic tools used in minimally invasive surgeries, supporting specialties like gynecology and general surgery across hospitals in the United States and Europe.

Tomorrow.io is a Boston-headquartered SaaS weather intelligence platform delivering real-time forecasts customized for industries. Clients including NFL, Uber, Delta Airlines, Ford, and National Grid use its tools across North America, Latin America, Europe, and Asia to predict weather impacts on operations.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Abeja Inc is a platform that integrates state-of-the-art AI technologies including IoT, big data, and deep learning. It provides the processes necessary for DX execution, including data generation, collection, processing, analysis, and AI modeling, and performs continuous and stable operations.

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

REPLOID Group AG is an Austrian industrial biotechnology company that specializes in transforming organic side streams such as food waste and agricultural residues into valuable end-products using Black Soldier Fly (BSF) larvae through their proprietary ReFarmUnit technology.